Authors




Sophia Z. Humphreys, PharmD, MHA

Latest:

Resources for Patients and Providers on Adalimumab Biosimilars

Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.



Mary Caffrey

Latest:

PBMs Drive Up Drug Costs, Squeeze Out Generics and Biosimilars, FTC Report Finds

A long-awaited report from the Federal Trade Commission (FTC) finds that vertical integration and consolidation have worked against consumers and independent pharmacies.


Deana Ferreri, PhD

Latest:

Postmarketing Surveillance Data Reinforce Trastuzumab Biosimilar Safety in HER2+ Gastric Cancer

CT-P6 demonstrates strong efficacy and safety in HER2-positive advanced gastric cancer, achieving an 82% disease control rate in real-world settings.


Sonia T. Oskouei, PharmD, BCMAS, DPLA

Latest:

Opinion: Is the Ophthalmology Market Ready to Embrace Biosimilars?

Samsung Bioepis has filed for FDA approval for a ranibizumab biosimilar candidate (SB11), and more ophthalmology biosimilars are in the pipeline.




Stacie Ropka, JD, PhD

Latest:

Opinion: Purple Book Patent Listings Are Only a First Step

Intellectual property attorneys from Axinn discuss the limitations of the Purple Book patent disclosure requirements and the burden these impose on biosimilar developers.



Gregory F. Schimizzi, MD

Latest:

Biosimilar Nonmedical Switching Must Never Undermine Patient Safety

While managing costs is extremely important to physicians and their patients, achieving and maintaining disease control without increasing the risk of complications or toxicities must remain the primary goal in the treatment of chronic inflammatory diseases.



Isha Bangia, PharmD, MBA

Latest:

Contributor: Drug Delivery Devices Help Originator Companies Retain Market Share

Amgen's Onpro autoinjector device for pegfilgrastim is a stunning example of how product differentiation via drug delivery devices can protect market share in the biologics market.




Marj P. Zimmerman, BSPharm, MS, Stanton R. Mehr

Latest:

Supportive Care in Oncology Therapy: Pegfilgrastim Biosimilars in the Pipeline

Pegylated version (pegfilgrastim) Neulasta® is the more commonly prescribed agent, with a significantly longer half-life than its predecessor and is the preferred in patients receiving cancer chemotherapy.


Laura Joszt

Latest:

Australian Study Reveals Significant Cost Savings and Market Impact From Biosimilars

Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price competition in the pharmaceutical market.


The Center for Biosimilars Staff

Latest:

Webinar: Streamlining the Regulatory Process to Advance Access to Biosimilars

This webinar celebrating Global Biosimilars Week was hosted by The Center for Biosimilars® in partnership with the International Generics and Biosimilars Association.


Jaime Rosenberg

Latest:

Part D Beneficiaries May Pay More for Some Generics, Biosimilars Than Brand-Name Drugs

Medicare Part D enrollees may actually pay more for some generic drugs than they would for their brand-name counterparts because of the Part D benefit, according to findings of a new study appearing in Health Affairs.



Theodore Bosworth

Latest:

Phase 3 Study Confirms Clinical Equivalence for ABP 980 and Reference Trastuzumab

Complete phase 3 data show that a biosimilar almost beat reference trastuzumab (Herceptin) for the primary endpoint of pathologic complete response in patients with HER2-positive early breast cancer.



Samantha DiGrande

Latest:

AAM's Christine Simmon on Biosimilars Council Initiatives and Educating Around Interchangeability

After the Association for Accessible Medicines’ (AAM’s) Access! 2019 annual meeting came to a close last week, The Center for Biosimilars® spoke with Christine Simmon, senior vice president of policy and strategic alliances, AAM, and executive director, AAM’s Biosimilars Council, to get her take on some of the outcomes of the meeting.



Kaitlynn Ely

Latest:

Rituximab Induction Is Cost Effective for Asymptomatic Advanced Follicular Lymphoma

Rituximab induction therapy has the highest probability of cost effectiveness in treating newly diagnosed patients with asymptomatic advanced follicular lymphoma, according to a study published in the British Journal of Haematology.


Joseph P. Fuhr, PhD

Latest:

Expect Shakeout Amid Biosimilar Market Growth

The biosimilar market is headed for a fork in the road, and the road taken will lead to savings and access or less competition and stiffer regulation.


Christina Mattina

Latest:

Real-World Evidence Supports Biosimilar HLX02 in Metastatic Breast Cancer

HLX02 shows promise as a safe, effective trastuzumab biosimilar for HER2-positive metastatic breast cancer, enhancing treatment access and affordability.



The Center for Biosimilars

Latest:

Novartis to Make Sandoz a Stand-alone Company

The move will create Europe's largest generics company.

© 2025 MJH Life Sciences

All rights reserved.